Skip to content
Open access

Site-selective acylation of human insulin to engineer a long-acting monovalent insulin-Fc conjugate.

Sep 2026 · RSC Medicinal Chemistry · Vol 17, pp. 5090-5100 · 0 citations
Medicine

TL;DR

Overall, the method of site-selective acylation and Fc conjugation to tune the basal-leaning pharmacology of insulin is described here the method of site-selective acylation and Fc conjugation to tune the basal-leaning pharmacology of insulin.

Abstract

Basal insulin therapy requires sustained and low-variability of insulin exposure; however, natural human insulin is rapidly cleared, thus necessitating frequent subcutaneous injections. Here we report a modular chemical platform for constructing monovalent insulin-Fc conjugates with structural homogeneity and long-term action. Site-selective acylation on three accessible amines of insulin (GlyA1, PheB1, or LysB29) yields a panel of alkynyl insulin analogs (3a-3c), which could couple with an azido Fc protein by CuAAC to produce monovalent insulin-Fc conjugates. Among these conjugates, Fc conjugation at LysB29 of insulin, namely 3c-Fc, retains the bioactivity, while insulin at GlyA1 (3a-Fc) and PheB1 (3b-Fc) were markedly deactivated, as assessed by the downstream Akt phosphorylation test. In vivo, the 3c-Fc conjugate exhibits a long pharmacokinetic and pharmacodynamic profile, which may result from the increase in the molecular size, the recycling by the neonatal Fc receptor, and the monovalence for slow insulin receptor-mediated clearance. Overall, we describe here the method of site-selective acylation and Fc conjugation to tune the basal-leaning pharmacology of insulin.

Read PDF

Similar papers

Open access Oct 2026

An Alternative Strategy for Albumin Binding in Therapeutics. Proof-of-Concept Synthesis of Metallacarborane−Insulin Conjugates

Commercialized designs of long-acting insulins often base their protracted mode of action on fatty acid acylation, which enables interaction between insulin and serum albumin. Building on that experience, we propose an alternative design where fatty acids are replaced with self-assembling, highly albumin-affine metal...

Jakub Cebula, Krzysztof Fink, W. Goldeman et al. · 1 citation
Nov 2026

Development of an albumin-binding domain-fused GLP-1 analog: Structural insights, receptor activation, and functional characterization.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are established therapeutic agents for metabolic disease, whereas the pharmacological use of native GLP-1 is constrained by its extremely short circulating lifetime. Alb8-GA, a G-related albumin-binding domain, binds human serum albumin (HSA) with high affinity. Here...

M. Abolhassan, Zamara Mariam, Arpita Prasad et al. · 0 citations
Oct 2026

Development of Long-Acting Teriparatide Analogues through Iterative Peptide Scanning and Site-Specific Modification by Serine/Threonine Ligation.

Teriparatide, the only FDA-approved osteoanabolic drug for osteoporosis, suffers from poor metabolic stability and requires frequent subcutaneous injections, leading to suboptimal patient compliance. To find optimized teriparatide derivatives, we herein report an iterative peptide scanning strategy followed by a serine...

Bi-Yao Liu, Kai-Xuan Song, Hong-Li Sui et al. · 0 citations
Sep 2026

Discovery of Novel GPR119 Agonists with Improved Kinetic Solubility and Drug-like Properties for Type 2 Diabetes Treatment.

Compound 18f outperformed the antidiabetic effect of sitagliptin as the DPP-4 inhibitor in female Zucker Diabetic Fatty rats and underscores its potential as a promising lead compound for type 2 diabetes treatment.

Jaeki Min, Jihun Kim, Kyeongwon Moon et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.